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v VCP expression is relatively higher in TNBC cell
lines than non-TNBC cell lines.
v VCP binds with SOX9 in TNBC as shown by IP
analysis.
v VCP regulates SOX9 downstream gene
expression (RGCC and PRTN3) in TNBC.
v Knockdown of VCP suppresses TNBC cell growth.
Hypothesis
VCP knockdown disrupts the function of SOX9 and
reduces cancer cell growth and survival in TNBC
Introduction
v Oncomine Analysis: VCP mRNA expression and
5-year overall survival rates were compared for six
different breast cancer datasets (6).
v qRT-PCR and Western Blotting Assay: mRNA
levels and protein level of indicated factors were
examined by qRT-PCR and Western blotting
assays.
v siRNA transfection for VCP knockdown:
Transfection of cells was performed with a pool of
three independent siRNA duplexes targeting VCP
for 48 hours.
v Cell Growth Assay: After treatment with siRNA for
48 hours, cells were harvested and reseeded into
24-well plates. Cell number was recorded by
Countess Automated Cell counter (Invitrogen, Life
Technologies, Grand Island, NY) on Day 1, 3, 5, 7.
v Immunoprecipitation: used to detect VCP as a
SOX9 binding protein
v Bioinformatic Analysis: mRNA-seq data were
analyzed by Drs. Ganiraju Manyam and Wenyi
Wang from the Department of Bioinformatics and
Computational Biology, Department of
Biostatistics, The University of Texas MD
Anderson Cancer Center.
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VCP and SOX9 Binding
VCP Knockdown and Cell Growth
SOX9 and VCP Expression 
There are few effective targeted therapies available for
triple-negative breast cancers (TNBCs), the most
aggressive form of breast cancer (1, 2). A better
understanding of critical molecular regulators of TNBC
is necessary to develop effective targeted therapies.
We previously determined that the transcription factors
SOX9 is highly expressed in TNBCs and is required
for TNBC cell survival and metastasis (3, 4). However,
SOX9 is difficult to target directly for therapeutics
development, so it is of great interest to evaluate more
druggable SOX9 binding proteins as potential targets.
Valosin-containing protein (VCP) is a member of the
AAA-ATPase superfamily whose elevated expression
is correlated with increased metastatic potential and
poor prognosis in some cancers (5). VCP has been




Figure 2. Analysis of SOX9 and VCP expression in 3 Non-TNBC cell lines
and 8 TNBC cell lines. A. Western blotting analysis shows that SOX9 has a
higher presence in TNBC cell lines (blue lanes) than Non-TNBC cell lines
(black lanes). B. VCP also has a higher presence in TNBC cell lines than
Non-TNBC cell lines. Vinculin was included as a load control. C. Higher
mRNA expression of SOX9 (first row) and VCP (bottom two rows) in TNBC
vs. Non-TNBC cell lines. Colors are z-score normalized to depict relative
values within rows. The Oncomine™ Platform (Thermo Fisher, Ann Arbor, MI)
was used for analysis and visualization.
Figure 1. VCP plays critical role in
TNBC. A. VCP presents relatively
higher expression level in TNBCs
than non-TNBCs. B. Expression of
VCP correlated with SOX9
expression C. VCP high expression
is associated with worse survival





VCP Regulates SOX9 Downstream Genes 
Figure 3. IP: VCP binds to SOX9
A. Western blotting analysis of IP
in MDA MB-231.
B. Immunoprecipitation to
determine VCP as a SOX9
binding protein. Graphic created
using BioRender software.
Figure 4. Knockdown of VCP in MDA MB-231 suppressed cell growth in
vitro. Cells were treated with siLuc, siVCP ORF, and siVCP 3’UTR for 48
hours before harvest and reseeding.
A. Western blotting analysis showing successful knockdown of VCP in
siVCP ORF and siVCP 3’UTR. VCP was only present in the control.
B. Cell growth curve. Cells were harvested and reseeded into 24-well
plates after treatment with siRNA. Cell number was recorded on day 1,
3, 5, and 7 using the Countess Automated Cell. **: p< 0.01; ***: p< 0.001
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Figure 5. Knockdown of VCP reduces SOX9 downstream gene
expression in MDA MB-468. A. Western blotting assay showing
successful knockdown of VCP with no protein present in siRNA treated
samples. B. Knockdown of VCP reduces relative mRNA expression of
SOX9 downstream genes
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VCP Cell Line Western Blot 
v Perform qRT-PCR to evaluate mRNA levels of
VCP in TNBC and non-TNBC cell lines.
v Further confirm the effect of VCP expression on
TNBC cell growth and invasion through
overexpression and knockout in TNBC cell lines
v Determine the effect of VCP inhibition on tumor
growth in vivo.
v Investigate other SOX9 binding proteins such as
CAV1 and GSK-3β as potential therapeutic targets
in TNBC.
Future Plans
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VCP Knockdown Western Blot
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